Detection of Early Lung Cancer among Military Personnel (DECAMP)
Technical Report,30 Sep 2017,29 Sep 2018
Boston University Boston United States
Pagination or Media Count:
The purpose of this work is to develop and validate molecular biomarkers found in blood, tissues, or other bodily fluids, which may be used for the early detection of lung cancer among military personnel and veterans. Over the course of the seventh year of this award, we have made significant progress towards enrollment in both clinical trials. We have recruited 85 percent of the 500 total subjects in the indeterminate pulmonary nodule study Protocol 1, and 66 percent of the 800 total subjects in the longitudinal screening study Protocol 2. We also held an in-person meeting in order to facilitate recruitment, brainstorm new scientific directions, and discuss potential avenues for ensuring DECAMPs longevity. The Leadership, Steering, Adjudication, Biostatistics, Imaging and Biomarker Committees continue to meet regularly. Most notably, significant progress has been made in adjudication of cases and controls within DECAMP-1 which will facilitate the validation of our cancer biomarkers. We have also begun to explore potential new assays and sequencing platforms in support of our scientific aims. Lastly, we have secured additional funding for the DECAMP consortium through July 2022, to ensure the completion of our enrollment goals and study aims.
- Medicine and Medical Research